Daiichi Sankyo reported a voluntary partial hold on recruitment and enrollment in the phase III IDeate‑Lung02 study of antibody‑drug conjugate ifinatamab deruxtecan after a higher‑than‑anticipated incidence of grade‑5 interstitial lung disease events and associated patient deaths. The company did not disclose the exact death count. The pause will trigger safety reviews and potential protocol amendments. The action underscores heightened regulatory scrutiny around pulmonary toxicity with certain ADCs and will affect timelines for registration and partnering decisions tied to the program.